The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than MibefradilBui, P. H.; Quesada, A.; Handforth, A.; Hankinson, O. · Drug Metabolism and Disposition · 2008

Metabolism of the calcium antagonist, mibefradil (POSICORTM, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and manWILTSHIRE, H. R.; SUTTON, B. M.; HEEPS, G.; BETTY, A. M.; ANGUS, D. W.; HARRIS, S. R.; WORTH, E.; WELKER, H. A. · Xenobiotica · 1997

Mibefradil: the sole exceptionK Weerasuriya · 1998

Clinical Pharmacokinetics of MibefradilDr Horst A. Welker, Hugh Wiltshire, Roy Bullingham · 1998

MibefradilRex N. Brogden, Anthony Markham · 1997

Mibefradil - an example of ‘overprecipitous approval’?1998

First markets for mibefradil1997

QUO VADISDr Wayne Elwood · 1998

Atorvastatin may AVERT angioplasty in CADDr Wayne Elwood · 1998

AbacavirDr Wayne Elwood · 1998

LipodystrophyDr Wayne Elwood · 1998

Pharmacists in the futureDr Wayne Elwood · 1998

Spot the difference with acne therapiesDr Wayne Elwood · 1998

Turning back the clock with telomerase?Dr Wayne Elwood · 1998